Lisata Therapeutics Inc
NASDAQ:LSTA

Watchlist Manager
Lisata Therapeutics Inc Logo
Lisata Therapeutics Inc
NASDAQ:LSTA
Watchlist
Price: 2.18 USD Market Closed
Market Cap: 19.2m USD

Net Margin

-1 704.9%
Current
Improving
by 145.8%
vs 3-y average of -1 850.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 704.9%
=
Net Income
$-18.2m
/
Revenue
$1.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 704.9%
=
Net Income
$-18.2m
/
Revenue
$1.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
Lisata Therapeutics Inc
NASDAQ:LSTA
18.9m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-1 704.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Lisata Therapeutics Inc
Glance View

Market Cap
19.2m USD
Industry
Biotechnology

Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

LSTA Intrinsic Value
8.76 USD
Undervaluation 75%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 704.9%
=
Net Income
$-18.2m
/
Revenue
$1.1m
What is Lisata Therapeutics Inc's current Net Margin?

The current Net Margin for Lisata Therapeutics Inc is -1 704.9%, which is above its 3-year median of -1 850.7%.

How has Net Margin changed over time?

Over the last 9 months, Lisata Therapeutics Inc’s Net Margin has increased from -1 998.5% to -1 704.9%. During this period, it reached a low of -1 998.5% on Dec 31, 2024 and a high of -1 704.9% on Oct 30, 2025.

Back to Top